TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
119 hedge funds and large institutions have $572M invested in TCR2 Therapeutics Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 23 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
8% less funds holding
Funds holding: 129 → 119 (-10)
31% less capital invested
Capital invested by funds: $834M → $572M (-$263M)
43% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 23
76% less call options, than puts
Call options by funds: $1.46M | Put options by funds: $6.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.04M |
| 3 |
Morgan Stanley
New York
|
+$3.13M |
| 4 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$2.66M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$22.1M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$11.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.49M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$7.57M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.71M |
TCRR Hedge Fund Activity: Q2 2021 in Review
119 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2021, worth a combined $572M — down 31% from $834M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TCRR and 13 opened new positions — a net loss of 10 holders — while 34 trimmed existing stakes and 49 added.
The largest buyer was Candriam SCA, adding an estimated $10.9M. The largest seller was Victory Capital Management, cutting an estimated $22.1M.
- 119 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2021, down from 129 in Q1 2021.
- Funds reported $572M of TCR2 Therapeutics Inc. Common Stock stock for Q2 2021, down 31% quarter-over-quarter.
- 13 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2021 and 23 closed out, a net change of -10 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q2 2021 was Candriam SCA, an estimated $10.9M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2021 was Victory Capital Management, an estimated $22.1M sold.
Based on aggregated 13F filings for Q2 2021.